Analysts polled by FactSet expected $2.52.

Reported sales for the fiscal quarter ended Sept. 27 were $25.40 billion, up from $23.99 billion a year earlier.

Analysts polled by FactSet expected $25.38 billion.

For fiscal 2026, the pharmaceuticals major lifted its projected adjusted EPS guidance to between $11.05 and $11.15 from a previous range of $10.96 to $11.11.

Analysts polled by FactSet expect $11.19

The company lifted its reported sales for fiscal 2026 to be between $101.0 billion and $101.4 billion from a previous range of $100.8 billion to $101.4 billion.

Analysts polled by FactSet expect $101.33 billion.

Shares of the company were down 1.7% in Tuesday premarket activity.

http://www.mtnewswires.com
Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.